ProCE Banner Activity

CME

Advancing the Line With New Combination Therapies for Malignant Melanoma

Video

Watch this webcast with Evan J. Lipson, MD, on the latest evidence on combination therapies for advanced melanoma.

Physicians: maximum of 1.00 AMA PRA Category 1 Credit™ 

US Physicians: maximum of 1.00 Medical Knowledge MOC point

Released: September 12, 2023

Expiration: September 11, 2024

No longer available for credit.

Share

Faculty

C. Lance Cowey

C. Lance Cowey, MD

Medical Director
Division of Skin Malignancy Research and Treatment Center
Baylor-Sammons Cancer Center
Texas Oncology
Dallas, Texas

Evan J. Lipson

Evan J. Lipson, MD

Associate Professor of Oncology
Melanoma and Cancer Immunology Programs
Bloomberg-Kimmel Institute for Cancer Immunotherapy
Johns Hopkins University School of Medicine
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Provided by

Jointly provided by USF Health and Rockpointe

ProCE Banner
ProCE Banner

Supporters

Supported by educational grants from Eisai Inc. and Merck Sharp & Dohme LLC.

Eisai Inc.

Merck Sharp & Dohme, LLC

Target Audience

The intended audience for this educational initiative includes oncologists and other clinicians involved in the treatment of patients with melanoma

Program Learning Goal

The goal of this program is to improve the knowledge, confidence, competence, and performance of learners in understanding and applying the latest science and clinical trial data on current and emerging melanoma combination therapies for the treatment of malignant melanoma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate novel combination therapy regimens into the management of appropriate patients with previously untreated metastatic melanoma

  • Evaluate emerging combination regimens for the treatment of melanoma progressing on immune checkpoint inhibitors

  • Manage treatment-related adverse events in an evidence-based manner

Disclosure

Relevant Financial Relationships Disclosure

USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant financial relationships are listed below. All individuals not listed have no relevant financial relationships.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director

C. Lance Cowey, MD

Medical Director
Division of Skin Malignancy Research and Treatment Center
Baylor-Sammons Cancer Center
Texas Oncology
Dallas, Texas

Charles Lance Cowy, MD - Advisory board or panel fees from EMD Serono, Eisai, Merck, Regeneron, and Iovance Biotherapeutics.

Evan J. Lipson, MD

Associate Professor of Oncology
Melanoma and Cancer Immunology Programs
Bloomberg-Kimmel Institute for Cancer Immunotherapy
Johns Hopkins University School of Medicine
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Evan J. Lipson, MD - Advisory board or panel fees from Bristol-Myers Squibb. Additional advisory board or panel fees (relationships terminated) from CareDX, Eisai, Genentech, Instil Bio, Merck, Natera, Nektar Therapeutics, Pfizer, Rain Therapeutics, Regeneron, Replimune, and Sanofi. Consultancy fees from OncoSec. Additional consultancy fees (relationships terminated) from HUYA Bioscience International, Immunocore and Novartis. Grants/research support from Bristol-Myers Squibb, Merck, Regeneron, and Sanofi.

Content Reviewer- Lilia Correa-Selm, MD, FAAD, FACMS has no financial interests/relationships or affiliations in relation to this activity

USF Health Office of Continuing Professional Development and Rockpointe staff have no relevant financial interests/relationships or affiliations in relation to this activity.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, learners must follow these steps during the period from September 12, 2023, through September 11, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page
  2. Read the target audience, learning objectives, and faculty disclosures
  3. View and study the content in its entirety
  4. Submit answers to the post-test questions and evaluation questions online

Learners must successfully complete the post-test and evaluation to receive credit. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and Rockpointe. USF Health is accredited by the ACCME to provide continuing medical education for physicians.

USF Health designates this enduring activity for a maximum of 1 AMA PRA Category 1 CreditTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For information about accreditation of this activity, please email: cpdsupport@usf.edu

 

ABIM MOC RECOGNITION STATEMENT


Successful completion of the CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is USF Health’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

To receive CME credit and/or MOC points, you MUST pass the post-test and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through USF Health’s ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

Participants will earn MOC Points equivalent to the amount of CME credits claimed for the activity. USF Health will submit within 60 days the Participant’s MOC Points. No MOC certificates will be provided. Participants with questions regarding their Points, should contact USF Health at cpdsupport@usf.edu.